Sanofi Pasteur has revealed results from European trials, which showed a single dose of the Influenza A (H1N1) 2009 monovalent vaccines Panenza and Humenza induced a robust immune response in adults and children.
One dose of the Panenza or Humenza Influenza A (H1N1) 2009 monovalent vaccine was shown to induce a robust antibody response considered to be protective for 93% of adults aged 18 to 59, and 83% of adults 60 years and older.
In children aged three to 17, 94% of the study participants achieved an effective seroprotective antibody response.
Sanofi Pasteur president and CEO Wayne Pisano said that the positive results would help build public confidence in the vaccine.
“Humenza has the potential to expand pandemic production capacities and to increase the number of doses of vaccine available. Panenza may be considered by European authorities as the vaccine of choice to protect specific at-risk populations,” Pisano said.
The results were based on trials conducted in France and Finland. No serious adverse events were observed.
